Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12028806 | 0.93 | — | — | |
| SCHEMBL8640635 | 0.88 | OR51E2 (0.33) | CRBNLMNA | |
| Hydrochloric Acid SCHEMBL30832409 | 0.86 | LMNA (0.33) | LMNA | |
| SCHEMBL8640104 | 0.86 | LMNA (0.33) | ALDH1A1MAPK1POLBLMNA | |
| SCHEMBL7613904 | 0.84 | LMNA (0.38) | ALDH1A1MAPK1CRBNPOLBLMNA | |
| SCHEMBL26378538 | 0.84 | CRBN (0.31) | CRBN | |
| Hydrochloric Acid SCHEMBL10802250 | 0.82 | LMNA (0.40) | ALDH1A1MAPK1POLBLMNA | |
| SCHEMBL12405032 | 0.80 | TRIM24 (0.32) | ALDH1A1 | |
| SCHEMBL30384915 | 0.77 | — | — | |
| SCHEMBL21225681 | 0.73 | FKBP5 (0.36) | FKBP5CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | ALDH1A1 2624/4885MAPK1 94/4885FKBP5 4681/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2395/4885MAPK1 102/4885FKBP5 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.